Drug Trial Radar · NCT07460375
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
191
Planned (sponsor's estimate)
Start
Oct 14, 2026
Primary completion
Feb 2030
Study completion Aug 2030
Sponsor
- Lead sponsor
- LigaChem Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- AntibodyChem Biosciences, Inc.
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.
Conditions
- Advanced Solid Tumors
Interventions
LCB02ADrug
CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of LCB02A (Phase 1 and 2)Time frame: Up to 48 months
- Recommended Phase 2 dose of LCB02A (Phase 1)Time frame: Up to 24 months
- Objective response rate (Phase 2)Time frame: Up to 24 months
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Mass General Hospital
Boston, Massachusetts · Not yet recruiting
START New York - Long Island
Lake Success, New York · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Not yet recruiting
MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Princess Margaret Hospital
Toronto, Ontario, Canada · Recruiting
Seoul National University Hospital
Seoul, South Korea · Not yet recruiting
ASAN Medical Center
Seoul, South Korea · Not yet recruiting
Samsung Medical Center
Seoul, South Korea · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.